<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347472">
  <stage>Registered</stage>
  <submitdate>12/09/2011</submitdate>
  <approvaldate>13/09/2011</approvaldate>
  <actrnumber>ACTRN12611000977976</actrnumber>
  <trial_identification>
    <studytitle>Intra-articular injections of hyaluronic acid in 
osteoarthritis of the sub-talar joint: 
A prospective study</studytitle>
    <scientifictitle>In patients with subtalar osteoarthritis, does hyaluronic acid improve pain and daily function?</scientifictitle>
    <utrn>U1111-1124-5158</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>arthritis of the subtalar joint</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intra-articular injections of 10 mg HA were administered weekly to the sub-talar joint for 3 weeks</interventions>
    <comparator>none</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>ankle hind foot score</outcome>
      <timepoint>4,12,28 weeks post treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The VAS questionnaire consisted of a series of questions, each with a score that ranged from 1 to 10.  The questionnaire evaluated the degree of pain, joint stiffness and functional disabilities.</outcome>
      <timepoint>4,12,28 weeks post treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>We included patients suffering from OA of the sub-talar joint grades II-III according to Paley Hall sub-talar joint grading system and grades II-IV according to the Kellgren &amp; Lawrence. All patients complained of pain on motion or rest for at least 6 months and had swelling and tenderness of the sub-talar joint.</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria included non-walking patients, those with an ankylosed subtalar joint, suspected or proven previous sub-talar joint infection, and those with known hypersensitivity to hyaluronic acid, pregnant or lactating women, patients with concomitant disease that may affect joints, those with open wounds or skin ulcers, and those taking anticoagulants or having a prolonged bleeding time.  Patients who had undergone lower limb intra-articular injection or surgery, including arthroscopy, within the previous 6 months were also excluded.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Patients were recruited at our Foot And Ankle Referral Center of our University Hospital in the period 2008 to 2009. Patients were given a thorough explanation regarding the treatment, and gave their informed consent for inclusion, data collection and follow up.

Allocation was not concealed</concealment>
    <sequence>N/A</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>4/09/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>25</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Israel</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Meir University hospital</primarysponsorname>
    <primarysponsoraddress>Meir University Hospital
59 Tchernichovsky Street
Kfar-Saba
44281</primarysponsoraddress>
    <primarysponsorcountry>Israel</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Meir University hospital</fundingname>
      <fundingaddress>Meir University Hospital
59 Tchernichovsky Street
Kfar-Saba
44281</fundingaddress>
      <fundingcountry>Israel</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Omer Mei-Dan</sponsorname>
      <sponsoraddress>Moshav Bazra,
7 yonek hadvash st.
ZC 60944</sponsoraddress>
      <sponsorcountry>Israel</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The management for osteoarthritis (OA) of the sub-talar joint is primarily conservative. We evaluated the efficacy of intra-articular viscosupplementation with sodium hyaluronate (HA) in the management of OA of the sub-talar joint.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Institutional Review Board  - Meir university hospital</ethicname>
      <ethicaddress>59 Tchernichovsky Street
Kfar-Saba,
44281</ethicaddress>
      <ethicapprovaldate>4/09/2008</ethicapprovaldate>
      <hrec>0195-08-MMC</hrec>
      <ethicsubmitdate>7/08/2008</ethicsubmitdate>
      <ethiccountry>Israel</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Omer Mei-Dan</name>
      <address>Moshav Bazra,
7 yonek hadvash st.
ZC 60944</address>
      <phone>+972-9-747-2549</phone>
      <fax>+972-9-747-1293</fax>
      <email>omer@extremegate.com</email>
      <country>Israel</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Omer Mei-Dan</name>
      <address>Moshav Bazra,
7 yonek hadvash st.
ZC 60944</address>
      <phone>+972-9-747-2549</phone>
      <fax>+972-9-747-1293</fax>
      <email>omer@extremegate.com</email>
      <country>Israel</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Omer Mei-Dan</name>
      <address>Moshav Bazra,
7 yonek hadvash st.
ZC 60944</address>
      <phone>+972-9-747-2549</phone>
      <fax>+972-9-747-1293</fax>
      <email>omer@extremegate.com</email>
      <country>Israel</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>